Doxorubicin inhibits human DNA topoisomerase I
- PMID: 1318169
- DOI: 10.1007/BF00686403
Doxorubicin inhibits human DNA topoisomerase I
Abstract
Purified human DNA topoisomerase I was assayed quantitatively by enzyme titrations with supercoiled pHC624 DNA in the presence of 0-2.0 microM doxorubicin. Supercoiled and relaxed DNAs were resolved by agarose gel electrophoresis in the presence of ethidium bromide, and the percentage of conversion of supercoiled DNA to relaxed DNA was quantified by scanning microdensitometry. The inhibition of DNA topoisomerase I activity was measured at varying concentrations of doxorubicin. Doxorubicin inhibited enzyme activity at an IC50 value (the concentration required to inhibit 50% of the total activity) of 0.8 microM. Similar inhibition was observed for daunomycin, a structurally related anthracycline antitumor drug. These results indicate that anthracyclines inhibit human DNA topoisomerase I activity at concentrations that cause DNA damage and cytotoxicity in vivo.
Similar articles
-
Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.Carcinogenesis. 1993 Nov;14(11):2341-51. doi: 10.1093/carcin/14.11.2341. Carcinogenesis. 1993. PMID: 8242865
-
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.Cancer Res. 1989 Nov 1;49(21):5969-78. Cancer Res. 1989. PMID: 2551497
-
Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.Int J Oncol. 2003 Jul;23(1):159-63. Int J Oncol. 2003. PMID: 12792789
-
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.Semin Cancer Biol. 1991 Aug;2(4):235-44. Semin Cancer Biol. 1991. PMID: 1655118 Review.
-
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.Biochem Pharmacol. 1999 Apr 1;57(7):727-41. doi: 10.1016/s0006-2952(98)00307-4. Biochem Pharmacol. 1999. PMID: 10075079 Review.
Cited by
-
Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.BMC Cancer. 2012 Aug 31;12:381. doi: 10.1186/1471-2407-12-381. BMC Cancer. 2012. PMID: 22938713 Free PMC article.
-
Evaluation of age effects on doxorubicin-induced toxicity in mesenchymal stem cells.Med J Islam Repub Iran. 2017 Dec 17;31:98. doi: 10.14196/mjiri.31.98. eCollection 2017. Med J Islam Repub Iran. 2017. PMID: 29951399 Free PMC article.
-
Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors.JACC CardioOncol. 2020 Dec 15;2(5):690-706. doi: 10.1016/j.jaccao.2020.11.004. eCollection 2020 Dec. JACC CardioOncol. 2020. PMID: 34396283 Free PMC article.
-
Triphenyl Phosphine-Functionalized Chitosan Nanoparticles Enhanced Antitumor Efficiency Through Targeted Delivery of Doxorubicin to Mitochondria.Nanoscale Res Lett. 2017 Dec;12(1):158. doi: 10.1186/s11671-017-1931-1. Epub 2017 Feb 28. Nanoscale Res Lett. 2017. PMID: 28249375 Free PMC article.
-
Triggering autophagic cell death with a di-manganese(II) developmental therapeutic.Redox Biol. 2017 Aug;12:150-161. doi: 10.1016/j.redox.2017.01.024. Epub 2017 Feb 4. Redox Biol. 2017. PMID: 28236767 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials